肝がん診断の世界市場レポート 2024年

肝がん診断市場規模は近年力強く成長しています。2023年の91億9,000万米ドルから2024年には99億5,000万米ドルに、CAGR8.3％で拡大します。過去数年間に見られた拡大は、生検技術や病理組織学の進歩、バイオマーカー検出の進歩、スクリーニングプログラムの進化、遺伝子検査の進歩、肝臓画像診断モダリティの強化によるものです。

肝がん診断市場規模は、今後数年間で力強い成長が見込まれます。2028年の年間平均成長率（CAGR）は6.8％で、129億6,000万米ドルに成長します。予測期間中に予想される成長は、規制の変更と標準化、画像診断モダリティの重要性の増加、次世代シーケンシングの開発、スクリーニングプログラムの拡大と認知度、バイオマーカーに基づく検査への需要の高まりに起因しています。予測期間における主な動向には、罹患率と有病率の増加、画像技術の進歩、非侵襲的診断の重視、精密医療と個別化診断の採用、人工知能（AI）の統合などが含まれます。

肝臓がんの有病率の増加が予想され、肝がん診断市場の成長を牽引します。肝細胞の制御不能な増殖を特徴とする肝臓がんは、深刻な健康リスクをもたらします。肝がんの診断検査は、原発性肝がんの診断後、肝臓内または肝臓周辺のがん細胞の広がりの程度を判定する上で重要な役割を果たします。米国がん協会の報告によると、女性の肝臓がんおよび肝内胆管がんの新規症例が増加し、米国では2023年に13,230例に達することが明らかになった。米国における2023年の肝臓がんの新規推定症例総数は41,210例で、29,380人が死亡すると予想されています。このことは、この疾患の有病率の上昇により、肝がん診断の緊急の必要性を強調しています。

B型肝炎の有病率の増加は、肝がん診断市場をさらに押し上げると予想されます。B型肝炎は肝臓を侵すウイルス感染症で、急性および慢性の症状を引き起こす可能性があります。慢性B型肝炎患者には、肝臓の健康状態を評価し、肝障害やがんの兆候を発見するために定期的なモニタリングが不可欠です。米国疾病予防管理センターによると、5歳未満の子供600万人以上を含む約2億9600万人がB型肝炎に罹患しています。このようなB型肝炎の有病率の増加は、肝がん診断市場拡大の大きな要因となっています。

2023年の肝がん診断市場で最大の地域は北米でした。肝がん診断市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の肝がん診断市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 肝細胞がん
• 胆管がん
• 肝芽腫
• その他のタイプ
• 世界の肝がん診断市場、スクリーニング別セグメンテーション：、実績および予測、2018-2023年、2023-2028年、2033年
• 臨床検査
• イメージング
• 内視鏡検査
• 生検
• その他のスクリーニング
• 世界の肝がん診断市場、技術別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 蛍光In situハイブリダイゼーション（FISH）
• 比較ゲノムハイブリダイゼーション（CGH）
• 免疫組織化学（IHC）
• その他の技術
• 世界の肝がん診断市場、最終用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院と診断研究所
• 学術研究機関
• 製薬およびCRO研究所

第7章 地域および国の分析

• 世界の肝がん診断市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の肝がん診断市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 肝がん診断市場の競合情勢
• 肝がん診断市場の企業プロファイル
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Qiagen NV
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

“Liver Cancer Diagnostics Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on liver cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for liver cancer diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The liver cancer diagnostics market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Type: Hepatocellular Carcinoma; Cholangiocarcinoma; Hepatoblastoma; Other Types
• 2) By Screening: Laboratory Testing; Imaging; Endoscopy; Biopsy; Other Screenings
• 3) By Technology: Fluorescent In Situ Hybridization (FISH); Comparative Genomic Hybridization (CGH); Immunohistochemical (IHC); Other Technologies
• 4) By End Use: Hospitals And Diagnostic Laboratories; Academic And Research Institutes; Pharmaceutical And CRO Laboratories
• Companies Mentioned: Abbott Laboratories; F. Hoffmann-La Roche Ltd.; Qiagen NV; Thermo Fisher Scientific Inc.; Siemens Healthineers
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Liver cancer diagnostics encompass a range of techniques utilized for the identification and assessment of liver cancer, a malignancy originating in the liver. These methods play a crucial role in the early detection and diagnosis of liver cancer, utilizing both imaging and molecular testing.

Hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and other related forms constitute the primary types of cancer addressed in liver cancer diagnostics. Hepatocellular carcinoma (HCC) specifically pertains to the predominant liver cancer affecting individuals with cirrhosis and preexisting chronic liver disease. The screening process involves various approaches such as laboratory testing, imaging, endoscopy, biopsy, and others. Diverse technologies, including fluorescent in situ hybridization (FISH), comparative genomic hybridization (CGH), immunohistochemical (IHC), among others, are employed across different end uses, including hospitals and diagnostic laboratories, academic and research institutes, and pharmaceutical and CRO laboratories.

The liver cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides liver cancer diagnostics market statistics, including liver cancer diagnostics industry global market size, regional shares, competitors with a liver cancer diagnostics market share, detailed liver cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the liver cancer diagnostics industry. This liver cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liver cancer diagnostics market size has grown strongly in recent years. It will grow from $9.19 billion in 2023 to $9.95 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%. The expansion observed in the historical period can be credited to advancements in biopsy techniques and histopathology, the progress in biomarker detection, the evolution of screening programs, advancements in genetic testing, and enhancements in liver imaging modalities.

The liver cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $12.96 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The anticipated growth in the forecast period can be ascribed to regulatory changes and standardization, the increasing significance of imaging modalities, the development of next-generation sequencing, the expansion of screening programs and awareness, and the growing demand for biomarker-based testing. Key trends in the forecast period encompass an increase in incidence and prevalence, progress in imaging technologies, emphasis on non-invasive diagnostics, the adoption of precision medicine and personalized diagnostics, and the integration of artificial intelligence (AI).

The anticipated rise in the prevalence of liver cancer is set to drive the growth of the liver cancer diagnostics market. Liver cancer, characterized by the uncontrolled growth of liver cells, poses a severe health risk. Diagnostic tests for liver cancer play a crucial role in determining the extent of cancer cell spread within or around the liver following the diagnosis of primary liver carcinoma. A report from the American Cancer Society revealed an increase in new cases of liver and intrahepatic bile duct cancer among females, reaching 13,230 in 2023 in the United States. The total estimated new cases of liver cancer for 2023 in the US are 41,210, with an expected 29,380 fatalities. This underscores the pressing need for liver cancer diagnostics due to the escalating prevalence of the disease.

The growing prevalence of hepatitis B is anticipated to further boost the liver cancer diagnostics market. Hepatitis B, a viral infection affecting the liver, can lead to both acute and chronic conditions. Regular monitoring is essential for individuals with chronic hepatitis B to assess liver health and detect signs of liver damage or cancer. According to the Centers for Disease Control and Prevention, approximately 296 million people, including over 6 million children under the age of 5, are affected by hepatitis B. This growing prevalence of hepatitis B is a significant driver for the expansion of the liver cancer diagnostics market.

A prominent trend in the liver cancer diagnostics market is the focus on technological innovations. Leading companies in the market are investing in the development of innovative diagnostic technologies to enhance their market standing. In December 2021, Helio Health and Fulgent Genetics Inc. introduced HelioLiver, an advanced liquid biopsy test designed for the early detection of liver cancer. HelioLiver utilizes a multi-analyte blood test approach, incorporating serum protein indicators and cell-free DNA (cfDNA) methylation patterns. This innovative test has the potential to identify hepatocellular carcinoma (HCC), the most prevalent form of liver cancer, allowing for early-stage detection and more effective treatment options.

Major companies operating in the liver cancer diagnostics market are strategically pursuing partnerships and collaborations to enhance their market profitability. Such collaborations aim to achieve specific business objectives and goals. For example, in August 2021, 111 Inc., a Chinese digital health platform, entered into a strategic cooperation agreement with Suzhou Zelgen Biopharmaceuticals Co. This collaboration focuses on developing a comprehensive management platform for liver cancer patients in China, encompassing digital marketing, patient education, data analytics, and pricing monitoring.

In December 2022, Fujifilm Holdings Corporation acquired Inspirata, an oncology informatics and healthcare IT solutions provider, for an undisclosed amount. The acquisition included Dynamyx digital pathology technology and involved the integration of Inspirata's staff and clients into Fujifilm. This strategic move allows Fujifilm to expand its Synapse Enterprise Imaging portfolio, incorporating pathology data and images into electronic medical record systems to streamline cancer patient treatment and support care teams.

Major companies operating in the liver cancer diagnostics market report are Abbott Laboratories, F. Hoffmann-La Roche Ltd., Qiagen NV, Thermo Fisher Scientific Inc., Siemens Healthineers, Becton Dickinson & Company, Illumina Inc., Koninklijke Philips NV, Epigenomics AG, Charles Russell Bard, Hologic Inc., Digna Biotech SL, Biocept Inc., Danaher Corporation, Foundation Medicine Inc., Agilent Technologies Inc., Biocare Medical LLC, Genemed Biotechnologies Inc., Merck KGaA, Fujifilm Medical Systems USA Inc., GE Healthcare, Bio SB Inc., Advanced Cell Diagnostics Inc., Oxford Gene Technology, Leica Biosystems Nussloch GmbH, Exiqon A/S, BioGenex Laboratories Inc., OncoCyte Corporation, Guardant Health Inc., Exact Sciences Corporation, Grail Inc., Freenome Holdings Inc., Natera Inc., Personal Genome Diagnostics Inc., Thrive Earlier Detection Corp

North America was the largest region in the liver cancer diagnostics market in 2023. The regions covered in the liver cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the liver cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The liver cancer diagnostics market includes revenues earned by entities by liver transplants, CT scans, and liver function tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cancer diagnostics market also includes sales of In Vitro and Imaging Tools, AI tools, and ML tools which are used in providing liver cancer diagnostic services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Liver Cancer Diagnostics Market Characteristics

3. Liver Cancer Diagnostics Market Trends And Strategies

4. Liver Cancer Diagnostics Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Liver Cancer Diagnostics Market Size and Growth

• 5.1. Global Liver Cancer Diagnostics Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Liver Cancer Diagnostics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Liver Cancer Diagnostics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Liver Cancer Diagnostics Market Segmentation

• 6.1. Global Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hepatocellular Carcinoma
• Cholangiocarcinoma
• Hepatoblastoma
• Other Types
• 6.2. Global Liver Cancer Diagnostics Market, Segmentation By Screening:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Laboratory Testing
• Imaging
• Endoscopy
• Biopsy
• Other Screenings
• 6.3. Global Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Fluorescent In Situ Hybridization (FISH)
• Comparative Genomic Hybridization (CGH)
• Immunohistochemical (IHC)
• Other Technologies
• 6.4. Global Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals And Diagnostic Laboratories
• Academic And Research Institutes
• Pharmaceutical And CRO Laboratories

7. Liver Cancer Diagnostics Market Regional And Country Analysis

• 7.1. Global Liver Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Liver Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Liver Cancer Diagnostics Market

• 8.1. Asia-Pacific Liver Cancer Diagnostics Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Liver Cancer Diagnostics Market

• 9.1. China Liver Cancer Diagnostics Market Overview
• 9.2. China Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Liver Cancer Diagnostics Market

• 10.1. India Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Liver Cancer Diagnostics Market

• 11.1. Japan Liver Cancer Diagnostics Market Overview
• 11.2. Japan Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Liver Cancer Diagnostics Market

• 12.1. Australia Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Liver Cancer Diagnostics Market

• 13.1. Indonesia Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Liver Cancer Diagnostics Market

• 14.1. South Korea Liver Cancer Diagnostics Market Overview
• 14.2. South Korea Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Liver Cancer Diagnostics Market

• 15.1. Western Europe Liver Cancer Diagnostics Market Overview
• 15.2. Western Europe Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Liver Cancer Diagnostics Market

• 16.1. UK Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Liver Cancer Diagnostics Market

• 17.1. Germany Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Liver Cancer Diagnostics Market

• 18.1. France Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Liver Cancer Diagnostics Market

• 19.1. Italy Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Liver Cancer Diagnostics Market

• 20.1. Spain Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Liver Cancer Diagnostics Market

• 21.1. Eastern Europe Liver Cancer Diagnostics Market Overview
• 21.2. Eastern Europe Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Liver Cancer Diagnostics Market

• 22.1. Russia Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Liver Cancer Diagnostics Market

• 23.1. North America Liver Cancer Diagnostics Market Overview
• 23.2. North America Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Liver Cancer Diagnostics Market

• 24.1. USA Liver Cancer Diagnostics Market Overview
• 24.2. USA Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Liver Cancer Diagnostics Market

• 25.1. Canada Liver Cancer Diagnostics Market Overview
• 25.2. Canada Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Liver Cancer Diagnostics Market

• 26.1. South America Liver Cancer Diagnostics Market Overview
• 26.2. South America Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Liver Cancer Diagnostics Market

• 27.1. Brazil Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Liver Cancer Diagnostics Market

• 28.1. Middle East Liver Cancer Diagnostics Market Overview
• 28.2. Middle East Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Liver Cancer Diagnostics Market

• 29.1. Africa Liver Cancer Diagnostics Market Overview
• 29.2. Africa Liver Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Liver Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Liver Cancer Diagnostics Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Liver Cancer Diagnostics Market Competitive Landscape And Company Profiles

• 30.1. Liver Cancer Diagnostics Market Competitive Landscape
• 30.2. Liver Cancer Diagnostics Market Company Profiles
  • 30.2.1. Abbott Laboratories
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. F. Hoffmann-La Roche Ltd.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Qiagen NV
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Thermo Fisher Scientific Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Siemens Healthineers
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Liver Cancer Diagnostics Market Competitive Benchmarking

32. Global Liver Cancer Diagnostics Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Liver Cancer Diagnostics Market

34. Liver Cancer Diagnostics Market Future Outlook and Potential Analysis

• 34.1 Liver Cancer Diagnostics Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Liver Cancer Diagnostics Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Liver Cancer Diagnostics Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer